FDA Questions Efficacy Of Novartis Inhaled CF Treatment

Law360, Washington (August 31, 2012, 3:39 PM EDT) -- U.S. Food and Drug Administration staffers have questioned whether Novartis AG's inhaled powder form of a cystic fibrosis treatment is effective enough to warrant agency approval, according to documents posted to the agency's website Friday.

In background documents for Wednesday's anti-infective drug advisory committee meeting, staffers expressed concerns that clinical trial data for Novartis' powder formulation of tobramycin — which is used to treat Pseudomonas aeruginosa in cystic fibrosis patients — wasn't robust enough.

Novartis has already had intravenous and inhaled solution versions of tobramycin approved...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.